This course is intended for all professionals involved in radiology with a particular emphasis on practicing radiologists, and trainees in radiology. A Practical and Current Approach for Managing Incidental Findings is specifically aimed at how incidental findings should be managed.
Statement of Need:
Changes brought about by healthcare reform are having many major impacts on the practice and economics of imaging. Central to this is the need to transform from the pay-for-service to value adding paradigm. One important component of adding value is only doing what is appropriate and safe, and this will soon be linked to a federal mandate and reimbursement. Directly related to this requirement, managing incidental likely asymptomatic imaging findings has become the relevant theme driving metrics for efficiency and appropriateness.
Goals and Objectives:
After completing this course, the learner should be able to:
Identify and characterize relevant incidental findings.
Provide contemporary evidence-based solutions for how incidental findings should be managed.
Appropriately communicate recommendations for follow-up.
Disclosure of Commercial Interest:
ARRS staff involved with this activity have nothing to disclose. Below is a listing of activity's contributors and planners disclosures:
J. Kruskal is the recipient of a stipend and an author for Up-To-Date, Inc.
C. Menias has nothing to disclose.
S. Bhalla has nothing to disclose.
Module 1
R. Gupta is a consultant for, and a recipient of honoraria, from Bayer Pharma AG, Invivo Corp., Siemens, and Halyard Health. He is also a member of Bayer Pharma AG’s Speakers Bureau.
J. Kruskal is the recipient of a stipend and an author for Up-To-Date, Inc.
S. Venkatesh has nothing to disclose.
T. Desser has nothing to disclose.
A. Sekhar has nothing to disclose.
Module 2
J. Soto is an editor with Elsevier.
K. Mortele has nothing to disclose.
B. Siewert has nothing to disclose.
K. Talati has nothing to disclose.
J. Steinkeler has nothing to disclose.
Y. Wang has nothing to disclose.
Module 3
J. Leyendecker has nothing to disclose.
M. Taffel has nothing to disclose.
M. Lubner is a primary investigator and the recipient of grant funding from Philips, and Ethicon.
D. Kim is a co-founder and cop-owner of VirtuoCTC; the recipient of stock options and a member of the medical advisory board for Digitalartforms; and an investor and recipient of stock from Cellectar.
E. Silver has nothing to disclose.
J. Ogdec has nothing to disclose.
Module 4
N. Hindman has nothing to disclose.
Z. Wang has nothing to disclose.
K. Elsayes has nothing to disclose.
S. Verma has nothing to disclose.
S. Rothan has nothing to disclose.
M. Habra has nothing to disclose.
S. Yacob has nothing to disclose.
J. Ou has nothing to disclose.
Module 5
D. Baumgarten has nothing to disclose.
K. Maturen has nothing to disclose.
M. Horrow has nothing to disclose.
E. Hecht has nothing to disclose.
S. Laifer-Narin has nothing to disclose.
D. Wahl has nothing to disclose.
S. Rodgers has nothing to disclose.
M. Sakala has nothing to disclose.
Module 6
J. Ko is the recipient of an honorarium and a speaker for Siemens AG.
B. Elicker has nothing to disclose.
S. Bhalla has nothing to disclose.
S. Desai has nothing to disclose.
S. Copley has nothing to disclose.
Module 7
B. Little has nothing to disclose.
K. Cummings has nothing to disclose.
S. Patel has nothing to disclose.
G. Gladish has nothing to disclose.
E. Lee has nothing to disclose.
C. Jokerst has nothing to disclose.
Module 8
M. Kransdorf has nothing to disclose.
M. Murphey has nothing to disclose.
J. Baker has nothing to disclose.
J. Ni Mhuircheartaigh has nothing to disclose.
J. Wu has nothing to disclose.
J. Long has nothing to disclose.
Module 9
E. Lee has nothing to disclose.
G. Schooler has nothing to disclose.
R. Ayyala has nothing to disclose.
V. Ho has nothing to disclose.
A. Winant has nothing to disclose.
Module 10
A. Kamaya has nothing to disclose.
C. Wu is an author and the recipient of royalties from Elsevier.